Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1

J Joshua E. Reuss (Georgetown University, Washington, DC) S Sara Kuruvilla (London Health Sciences Centre, London, ON, Canada) N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) I Ibrahim Hanna Azar (IHA Hematology Oncology Consultants, Ypsilanti, MI) J Jill Feldman (Patient Advocate EGFR Resisters Deerfield Illinois USA) N Naoki Furuya (St Marianna University School of Medicine, Kawasaki, Japan) P Paul Wheatley-Price (The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada) L Logan Roof (Ohio State University, Columbus, OH) A Ana I. Velazquez Y Yubao Wang (Department of Cancer Biology, Dana-Farber Cancer Institute) N Natasha B. Leighl

Abstract

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .

Article Details

Volume / Issue Vol. 43, Issue 24
Published August 20, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

J

Joshua E. Reuss

Georgetown University, Washington, DC

S

Sara Kuruvilla

London Health Sciences Centre, London, ON, Canada

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

I

Ibrahim Hanna Azar

IHA Hematology Oncology Consultants, Ypsilanti, MI

J

Jill Feldman

Patient Advocate EGFR Resisters Deerfield Illinois USA

N

Naoki Furuya

St Marianna University School of Medicine, Kawasaki, Japan

P

Paul Wheatley-Price

The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

L

Logan Roof

Ohio State University, Columbus, OH

A

Ana I. Velazquez

Y

Yubao Wang

Department of Cancer Biology, Dana-Farber Cancer Institute

N

Natasha B. Leighl